Baicalein and baicalin as Zika virus inhibitors

At present, there is no effective antiviral agent for Zika virus (ZIKV), an arbovirus that is known for its teratogenic effects on newborns. Baicalein and baicalin were found to be capable of downregulating ZIKV replication up to 10 hours postinfection, while prophylactic effects were evident in pre...

Full description

Saved in:
Bibliographic Details
Published in:Archives of virology Vol. 164; no. 2; pp. 585 - 593
Main Authors: Oo, Adrian, Teoh, Boon Teong, Sam, Sing Sin, Bakar, Sazaly Abu, Zandi, Keivan
Format: Journal Article
Language:English
Published: Vienna Springer Vienna 01.02.2019
Springer Nature B.V
Subjects:
antiviral agents
arboviruses
Baicalin
binding capacity
Biomedical and Life Sciences
Biomedicine
Brief Report
glycoproteins
Infectious Diseases
Medical Microbiology
Neonates
protective effect
Replication
Teratogenicity
Virology
Zika virus
ISSN:0304-8608, 1432-8798, 1432-8798
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:At present, there is no effective antiviral agent for Zika virus (ZIKV), an arbovirus that is known for its teratogenic effects on newborns. Baicalein and baicalin were found to be capable of downregulating ZIKV replication up to 10 hours postinfection, while prophylactic effects were evident in pre-treated cells. Baicalein exhibited its highest potency during intracellular ZIKV replication, whereas baicalin was most effective against virus entry. Our in silico interaction assays predicted that both compounds exhibited the strongest binding affinities towards ZIKV NS5, while the virus envelope glycoprotein was the least likely target protein. These findings serve as a crucial platform for further in-depth studies to decipher the underlying anti-ZIKV mechanism(s) of each compound.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0304-8608
1432-8798
1432-8798
DOI:10.1007/s00705-018-4083-4